Insights

Commercial traction Denali Therapeutics reported its first quarterly revenue as a commercial-stage company with 3.6 million in net product revenue from AVLAYAH in Q2 2026, signaling market acceptance and potential for ongoing payer discussions and expansion opportunities in supportive neurodegenerative and lysosomal storage disease portfolios.

Neurology focus The company is actively commercializing a Hunter syndrome therapy (AVLAYAH) and pursuing programs that cross the blood-brain barrier, presenting a clear opportunity to target neurology-focused payers, patient access programs, and specialty pharmacies seeking CNS-directed biologics.

Strategic partnerships Past and recent collaboration activity includes milestone-driven revenue and a strategic home infusion partnership for AVLAYAH, indicating a receptiveness to channel partnerships and bundled services with specialty pharmacies to accelerate patient access and geographic reach.

Financial capacity With substantial funding and a revenue base in the mid hundreds of millions, alongside a sizeable funding runway, Denali has the financial backbone to support expanded clinical development, payer negotiations, field clinical teams, and outbound BD activities targeting large pharma and rare-disease players.

Clinical momentum Ongoing development of DNL593 and other TransportVehicle programs, plus FDA approvals and Phase 1/2 readouts anticipated by end of 2026, create upsell and partnership opportunities with CROs, contract manufacturers, and specialty distributors seeking early access and joint development capabilities.

Similar companies to Denali Therapeutics

Denali Therapeutics Tech Stack

Denali Therapeutics uses 8 technology products and services including MATLAB, Amazon Web Services, HashiCorp Terraform, and more. Explore Denali Therapeutics's tech stack below.

Media & News

Denali Therapeutics's Email Address Formats

Denali Therapeutics uses at least 5 email formats:
Denali Therapeutics Email FormatsExamplePercentage
FLast@denalitherapeutics.comJDoe@denalitherapeutics.com
75%
First@denalitherapeutics.comJohn@denalitherapeutics.com
25%
FLast@dnli.comJDoe@dnli.com
68%
Last@dnli.comDoe@dnli.com
29%
First.Last@dnli.comJohn.Doe@dnli.com
3%

Frequently Asked Questions

What is Denali Therapeutics's stock symbol?

Minus sign iconPlus sign icon
Denali Therapeutics is a publicly traded company; the company's stock symbol is DNLI.

What is Denali Therapeutics's official website and social media links?

Minus sign iconPlus sign icon
Denali Therapeutics's official website is denalitherapeutics.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does Denali Therapeutics generate?

Minus sign iconPlus sign icon
As of October 2026, Denali Therapeutics's annual revenue is estimated to be $250M - $500M.

What is Denali Therapeutics's SIC code and NAICS code?

Minus sign iconPlus sign icon
Denali Therapeutics's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Denali Therapeutics have currently?

Minus sign iconPlus sign icon
As of October 2026, Denali Therapeutics has approximately 607 employees across 4 continents, including North America, Europe and Asia. Key team members include Chief Scientific Officer, Head Of Discovery: J. L., Vice President International Business (ex-Us): A. C. and Vice President Of Biopharmaceutical Development: D. K. Explore Denali Therapeutics's employee directory with LeadIQ.

What industry does Denali Therapeutics belong to?

Minus sign iconPlus sign icon
Denali Therapeutics operates in the Biotechnology Research industry.

What technology does Denali Therapeutics use?

Minus sign iconPlus sign icon
Denali Therapeutics's tech stack includes MATLAB, Amazon Web Services, HashiCorp Terraform, Cloudinary, Microsoft SharePoint, Segment, DocuSign and Smartsheet.

What is Denali Therapeutics's email format?

Minus sign iconPlus sign icon
Denali Therapeutics's email format typically follows the pattern of FLast@denalitherapeutics.com. Find more Denali Therapeutics email formats with LeadIQ.

How much funding has Denali Therapeutics raised to date?

Minus sign iconPlus sign icon
As of October 2026, Denali Therapeutics has raised $1.3B in funding. The last funding round occurred on Mar 27, 2024 for $500M.

When was Denali Therapeutics founded?

Minus sign iconPlus sign icon
Denali Therapeutics was founded in 2015.
Denali Therapeutics logo

Denali Therapeutics

Biotechnology ResearchCalifornia, United States501-1000 Employees

Denali Therapeutics is a mid-sized biotechnology company based in South San Francisco, California, focused on developing therapies capable of crossing the blood-brain barrier. It uses a proprietary TransportVehicle platform to discover, develop, and deliver medicines for neurodegenerative and other serious diseases, including lysosomal storage disorders. The company operates within the biotechnology research sector, pursuing treatments that address central nervous system-related conditions. It is advancing programs such as DNL593, designed to deliver progranulin to the brain using its TransportVehicle technology.

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
Stock Symbol
DNLI
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2015
Employees
501-1000

Section iconFunding & Financials

  • $1.3B

    Denali Therapeutics has raised a total of $1.3B of funding over 7 rounds. Their latest funding round was raised on Mar 27, 2024 in the amount of $500M as a Post IPO Equity.

  • $250M - $500M

    Denali Therapeutics's revenue is estimated to be in the range of $250M - $500M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.